Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

Simple item page
dc.contributor.affiliationUniversidad de Chile
dc.contributor.affiliationUniversidad de Santiago de Chile
dc.contributor.affiliationAutonomous University of Barcelona
dc.contributor.affiliationUniversidad de Las Americas - Chile
dc.contributor.affiliationUniversidad de Concepcion
dc.contributor.affiliationUniversidad del Desarrollo
dc.contributor.authorEscobar, Alejandro
dc.contributor.authorReyes-López, Felipe E.
dc.contributor.authorAcevedo, Monica L.
dc.contributor.authorAlonso-Palomares, Luis
dc.contributor.authorValiente-Echeverria, Fernando
dc.contributor.authorSoto-Rifo, Ricardo
dc.contributor.authorPortillo, Hugo
dc.contributor.authorGatica, Jimena
dc.contributor.authorFlores, Iván
dc.contributor.authorNova-Lamperti, Estefania
dc.contributor.authorBarrera-Avalos, Carlos
dc.contributor.authorBono, Maria Rosa
dc.contributor.authorVargas, Leonardo
dc.contributor.authorSimon, Valeska
dc.contributor.authorLeiva-Salcedo, Elias
dc.contributor.authorVial, Cecilia
dc.contributor.authorHormazabal, Juan
dc.contributor.authorCortes, Lina Jimena
dc.contributor.authorValdes, Daniel
dc.contributor.authorSandino, Ana M.
dc.contributor.authorImarai, Monica
dc.contributor.authorAcuña-Castillo, Claudio
dc.date.accessioned2022-02-22T17:41:32Z
dc.date.available2022-02-22T17:41:32Z
dc.date.issued2022-01-31
dc.description.abstractCoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
dc.description.sponsorshipFONDECYT Postdoctoral fellowship [SECTEI/138/2019]; FONDECYT [1211547, 1211841, 1201240, 1201664, 1181814, 1190156, 1180666]; DICYT [021943AC]; SOFOFA SiEMPRE [18 CTBT-102728]; The authors thank the support of ANID-COVID1005 (EN-L), ANID-COVID1038 (AMS, FER-L, MI, CA-C), FONDECYT Postdoctoral fellowship N degrees SECTEI/138/2019 (LA-P), FONDECYT grants 1211547 (FV-E), 1211841 (FER-L), 1201240 (CV, JH, and LC), 1201664 (MI, AMS, and FER-L), 1181814 (EL-S), 1190156 (RS-R), and 1180666 (AE); DICYT 021943AC (CA-C), SOFOFA SiEMPRE 18 CTBT-102728 (CV, JH, and LC). The funding bodies were not involved in the study design, collection, analysis and interpretation of data, the writing of this article, or the decision to submit results for publication.
dc.format.mimetypeapplication/pdf
dc.identifier.citationFrontiers in Immunology, 12, 766278. https://doi.org/10.3389/fimmu.2021.766278
dc.identifier.doihttps://doi.org/10.3389/fimmu.2021.766278
dc.identifier.folio1201240
dc.identifier.folio1201664
dc.identifier.folio1211547
dc.identifier.folio1211841
dc.identifier.folio1181814
dc.identifier.folio1190156
dc.identifier.folio1180666
dc.identifier.issn1664-3224
dc.identifier.orcidhttps://orcid.org/0000-0001-8767-9180
dc.identifier.orcidhttps://orcid.org/0000-0001-8119-5417
dc.identifier.orcidhttps://orcid.org/0000-0003-3607-6077
dc.identifier.orcidhttps://orcid.org/0000-0001-9156-2516
dc.identifier.orcidhttps://orcid.org/0000-0002-5001-457X
dc.identifier.orcidhttps://orcid.org/0000-0002-6555-1992
dc.identifier.orcidhttps://orcid.org/0000-0002-3862-3743
dc.identifier.orcidhttps://orcid.org/0000-0003-0726-2778
dc.identifier.orcidhttps://orcid.org/0000-0002-7673-0013
dc.identifier.orcidhttps://orcid.org/0009-0004-2987-8076
dc.identifier.orcidhttps://orcid.org/0000-0002-0399-6144
dc.identifier.orcidhttps://orcid.org/0000-0001-6487-5648
dc.identifier.pmid35173705
dc.identifier.researcheridG-7461-2014
dc.identifier.researcheridHZH-7245-2023
dc.identifier.researcheridAAJ-5510-2021
dc.identifier.researcheridI-2775-2013
dc.identifier.researcheridAAI-7090-2021
dc.identifier.researcheridI-6881-2018
dc.identifier.researcheridS-1760-2018
dc.identifier.researcheridAAQ-8288-2021
dc.identifier.researcheridAAH-6061-2021
dc.identifier.researcheridGVS-4266-2022
dc.identifier.rorhttps://ror.org/047gc3g35
dc.identifier.rorhttps://ror.org/02ma57s91
dc.identifier.rorhttps://ror.org/052g8jq94
dc.identifier.rorhttps://ror.org/0166e9x11
dc.identifier.rorhttps://ror.org/0460jpj73
dc.identifier.rorhttps://ror.org/05y33vv83
dc.identifier.rorhttps://ror.org/028ynny55
dc.identifier.scopusauthorid7101621507
dc.identifier.scopusauthorid36773500800
dc.identifier.scopusauthorid21740756300
dc.identifier.scopusauthorid57200411162
dc.identifier.scopusauthorid22137090600
dc.identifier.scopusauthorid16246230200
dc.identifier.scopusauthorid57452749600
dc.identifier.scopusauthorid57209010355
dc.identifier.scopusauthorid57209300780
dc.identifier.scopusauthorid36103012100
dc.identifier.scopusauthorid57195985435
dc.identifier.scopusauthorid7005331463
dc.identifier.scopusauthorid57224840744
dc.identifier.scopusauthorid35726887400
dc.identifier.scopusauthorid6505855876
dc.identifier.scopusauthorid55553152400
dc.identifier.scopusauthorid6603387260
dc.identifier.scopusauthorid57190170413
dc.identifier.scopusauthorid6602680747
dc.identifier.scopusauthorid6603906080
dc.identifier.scopusauthorid6504605634
dc.identifier.scopusauthorid6603281718
dc.identifier.urihttps://repositorio.udla.cl/handle/udla/945
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SA
dc.relation.fundingDICYT 021943AC, (CTBT-102728)
dc.relation.fundingFER-L
dc.relation.fundingAmerican Medical Systems, AMS, (1180666, 1181814, 1190156)
dc.relation.fundingAmerican Medical Systems, AMS
dc.relation.fundingFondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT, (1201240, 1201664, 1211547, 1211841, SECTEI/138/2019)
dc.relation.fundingFondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT
dc.relation.fundingFONDECYT Postdoctoral fellowship [SECTEI/138/2019]
dc.relation.fundingFONDECYT [1211547, 1211841, 1201240, 1201664, 1181814, 1190156, 1180666]
dc.relation.fundingDICYT [021943AC]
dc.relation.fundingSOFOFA SiEMPRE [18 CTBT-102728]
dc.relation.isindexedbyWeb of Science
dc.relation.issn1664-3224
dc.rightsCreative Commons Attribution 4.0 International
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceFRONTIERS IN IMMUNOLOGY
dc.source.urihttps://doi.org/10.3389/fimmu.2021.766278
dc.subjectCoronaVac
dc.subjectSARS-CoV-2
dc.subjectherd immunity
dc.subjectneutralizing antibodies
dc.subjectCOVID-19
dc.subjectvaccine
dc.subjectimmunological memory
dc.subject.lcshCOVID-19 (Disease)
dc.subject.lcshHerd immunity
dc.subject.lcshVaccines
dc.subject.lcshImmunologic memory
dc.subject.oecd13 Ciencias Médicas y de la Salud
dc.subject.oecd23.1 Medicina Básica
dc.subject.oecd33.1.3 Inmunología
dc.titleEvaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
dc.title.alternativeEvaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.
dc.typejournal article
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.udla.catalogadorCBM
oaire.citation.titleFRONTIERS IN IMMUNOLOGY
oaire.citation.volume12
oaire.fundingReference.awardNumber1201240
oaire.fundingReference.awardNumber1201664
oaire.fundingReference.awardNumber1211547
oaire.fundingReference.awardNumber1211841
oaire.fundingReference.awardNumber1181814
oaire.fundingReference.awardNumber1190156
oaire.fundingReference.awardNumber1180666
oaire.fundingReference.funderNameAgencia Nacional de Investigación y Desarrollo (ANID)
udla.curacion.controljmvg
udla.oecd.area3 Ciencias Médicas y de la Salud
udla.oecd.discipline3.1.3 Inmunología
udla.oecd.subarea3.1 Medicina Básica

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Escobar 2022 Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.pdf
Size:
3.49 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Investigación